Anka Tıp Dergisi
Yazarlar: Mustafa Sencer SEĞMEN, Selen ACEHAN, Akkan AVCİ, Müge GÜLEN, Salim SATAR
Konular:Temel Sağlık Hizmetleri
DOI:10.38175/phnx.623049
Anahtar Kelimeler:Antivenom,Emergency,Snakebite
Özet: Objective: Snake poisonings can cause severe morbidity and mortality. In this study, it was aimed to evaluate arrival times of the patients admitted to the Emergency Medicine Department with a diagnosis of snakebite, bitten areas, clinical manifestations, the need for antivenom doses, the relationship between the length of hospital stay and changes in blood biochemistry. Materials and Methods: The total number of 34 patients admitted to the Emergency Department of Adana Numune Education and Research Hospital between March 2011 and June 2013 were included in this study. In this study, arrival times of the patients admitted to the Emergency Medicine Department with a diagnosis of snakebite, bitten areas, clinical manifestations, the need for antivenom and their doses, the relationship between the length of hospital stay and changes in blood biochemistry were evaluated. Results: In our study, 9 (26.5%) patients were grade 0, 5 (14.7%) patients, were grade 1, 17 (50.0%) patients were grade 2, 3 (8.8% ) patients were grade 3. In the clinical follow-up of the patients, the rate of antivenom uptake and the amount of antivenom in patients stay in the hospital for more than 24 hours were significantly higher than the ones that stay in the hospital less than 24 hours. In our study, patients were divided into two groups according to the stages with stage 0-1 and stage 2-3, and doses of antivenoms that they take were compared. The mean dose of antivenom in the group of patients with stage 2-3 was 4.15 ± 2.06, and this value was 1.83 ± 1.17 in patients with stage 0-1. Conclusions: Despite high-dose antivenom therapy is recommended snake poisonings according to the staging, low-dose antivenom therapy should be considered instead of high-dose antivenom therapy and an additional dose of antivenom could be used according to the clinical follow-up.